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Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic 
Liver Transplant Patients Rescued With FK 506 
A.B. Jain, R. Venkataramanan, J. Fung, G. Burckart, J. Emeigh, W. Diven, V. Warty, K. Abu-Elmagd, 
S. Todo, M. Alessiani, and T.E. Starzl 
CYCLOSPORINE (CyA) has been used extensively in 
organ transplantation, but its use is limited by its 
nephrotoxicity. 1 FK S06 is a novel immunosuppressive 
drug that synergizes with CyA in in vitro and in animal 
studies.2•3 Combination therapy of FK S06 and CyA ap-
pears to be effective in clinical trials. However, prelimi-
nary animal studies have shown FK S06 to also be neph-
rotoxic.4 In initial clinical trials, combined use of CyA and 
FK S06 resulted in severe renal dysfunction.s The mecha-
nistic basis for this observation is not completely under-
stood. The aim of the present study is: (1) to evaluate the 
kinetics of CyA before and during FK S06 therapy in 
orthotopic liver transplant (OLTx) patients, in order to 
determine the presence of any pharmacokinetic drug inter-
action; (2) to determine the changes in serum creatinine 
during the study period; and (3) to monitor terminal 
disposition half-life of Cy A after the drug is discontinued in 
patients receiving FK S06 therapy. 
STUDY DESIGN 
The first seven consecutive OLTs who were on CyA for 23 
days to 7 years (median 3 years), and were switched to FK 
506, were selected for this study. There were four males 
and three females, ranging in age from 19 to 45 years, and 
in body weight from 49 to 100 kg. Intravenous (IV) CyA 
kinetic studies were performed one day prior to FK S06 
therapy (day 0); after 2 days of IV FK S06 therapy (0.15 
mg/kg per day) (n = 7), and after 7 days of FK S06 
treatment (O.lS mg/kg per day IV for 3 days and 0.3 mg/kg 
per dayPO for 4 days) (n = 4). Three patients discontinued 
CyA before 7 days of FK S06 therapy. On the study day, 
CyA was administered as a short IV infusion over 1.5 to 3 
hours, and multiple blood samples were collected over 24 
hours. Whole blood CyA concentrations were measured 
by HPLC, and various pharmacokinetic parameters were 
calculated according to standard methods.6 
In another 22 patients who were converted from CyA to 
FK S06, CyA blood concentrations were measured daily 
for 7 to 10 days (whole blood IDx) after discontinuation of 
CyA therapy. Terminal disposition rate constant (A) was 
calculated from linear regression analysis of log blood 
concentration versus time data, and the half-life was 
calculated as 0.693/A. 
Analysis of variance was used to determine the signifi-
cance of any differences in various pharmacokinetic pa-
rameters of CyA measured at different time perbds using 
a P value of .05. 
RESULTS 
The blood CyA concentration versus time profile in one 
patient on days 0, 2, and 7 is shown in Fig 1. Various 
pharmacokinetic parameters of CyA, during the three 
different study periods (days 0, 2, and 7 of FK 506 
treatment), are shown in Table 1 for each patient. The 
mean (±SD) half-life of CyA was 9.9 (±3.4) hours before 
FK S06 treatment, 10.4 (±3.1) after 2 days of FK 506 
treatment, and 9.0 (±3.1) after 7 daysofFKS06 treatment. 
Similarly, the clearance of CyAwas 5.6 (:!:3.3) mUmin per 
kilogram on day 0,6.5 (±3.3) on day 2, and 6.8 (±7.5) on 
day 7 (Table 2). None of the pharmacokinetic parameters 
were significantly different between the three study peri-
ods. FK S06 trough plasma concentrations on days 2 and 7 
are shown in Tables 2 and 3. FK 506 concentrations were 
2.9 (±2.2) ng/mLon day 2, and 2.0 (:!:1.4) ng/mL on day 7. 
The mean serum creatinine prior to FK 506 treatment 
was 1.6 (±0.7), which increased to a value of 3.0 (±1.3) 
after 7 days of FK S06 treatment in the presence of CyA. 
The renal function improved once CyA was discontinued, 
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Fig 1. Whole blood eyA concentration versus time curve in one 
patient on day 0 (_) (CyA dose of 80 mg): day 2 (b.) CyA dose of 
64 mg; and day 7 (0) (CyA dose of 80 mg) after FK 506 treatment. 
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Table 1. Pharamcoklnetlc Parameters of CyA 
ea~ Ufe (hours) Clearance (mUmin per kilogram) Volume of Distribution (Ukg) 
Patients Day 0 Day 2 Day 7 Day 0 
R.F. 9.3 12.8 
L.W. 14.6 13.0 6.1 
D.J. 10.4 10.8 13.6 8.5 
M.B. 8.5 11.2 7.0 4.1 
W.O. 4.3 5.6 17.0 0.9 
DW. 13.3 13.0 9.7 3.8 
HW. 9.6 6.7 9.9 
"" with a mean serum creatinine of 2.1 (± 0.9) (Table 2). 
These differences are statistically signific'lrnt (P = .045). 
In an additional 22 patients, the daily CyA concentra-
tions were measured by TDx after discontinuation of the 
last dose of CyA. In this group of patients, the half-life of 
CyA was more prolonged than what had been reported for 
CyA in transplant patients. The half-life was 31.5 to 67.2 
hours when serum bilirubin was 0.4 to 1.1 mgldL, and 38.4 
to 206.7 hours when the serum bilirubin was 2.3 to 50.9 
mgldL. 
DISCUSSION 
Significant nephrotoxicity has been reported in patients 
receiving FK 506 and CyA.s In the present study, we 
evaluated the presence of any pharmacokinetic interaction 
between FK 506 and CyA. Pharmacokinetics of CyA was 
studied over a dosing interval of 24 hours. The half-life of 
CyA in the present kinetic study, before and during FK 506 
treatment, is unchanged. These values are similar to the 
half-lives reported in the literature based on 24-hour ki-
netic studies.7•8 It is clear from this study that FK 506 does 
not alter any of the pharmacokinetic parameters of CyA, 
indicating that there is no pharmacokinetic interaction 
between these two drugs. 
After termination of CyA treatment, the half-life was 
approximately 3 days in patients with serum bilirubin of 
less than 1.2 mgldL, and was nearly 9 days in patients with 
high serum bilirubin (2 to 50 mgldL). Anecdotal reports 
indicate persistence of CyA in patients long after discon-
tinuation of CyA therapy. 9 It is possible that complete 
withdra'wal of CyA therapy after chronic CyA dosing 
Day 2 Day 7 Day 0 Day 2 Day 7 
7.8 5.4 5.0 
8.0 17.8 3.3 14.2 
2.9 1.5 2.1 1.7 0.7 
4.8 4.8 0.4 1.4 3.1 
4.0 3.1 2.6 3.1 1.3 
11.7 4.9 3.8 
rest.;lts in slow release of the drug from peripheral tissue 
compartments to the vascular compartment. In the pres-
ence of hepatic dysfunction, the clearance of Cy A is likely 
to be further decreased, and hence, the half-life is pro-
longed. Therefore, the observed long half-life of CyA in 
patients switched from CyA to FK 506 may not be 
mediated by FK 506. Indirect evidence for this is available 
from in vitro studies, where FK 506 inhibits the cy-
tochrome P-450 system responsible for CyA metabolism 
only at higher concentrations.10 At concentrations of FK 
506 corresponding to that observed clinically (Tables 2 and 
3), FK 506 does not appear to be an inhibitor of CyA 
metabolism. However, it was not possible to determine the 
effect of FK 506 on the elimination of CyA metabolites in 
this study. FK 506 may inhibit further metabolism or 
biliary excretion of CyA metabolites, and thereby prolong 
the half-life estimated based on TDx concentrations. Fur-
ther studies in animals are necessary to completely char-
acterize this interaction. Independent of the mechanism of 
the FK 506 and CyA interaction, it is our practice at the 
present time not to use this combination clinically, because 
of the significant impairment in renal function. 
In conclusion, there appears to be no pharmacokinetic 
drug interaction between CyA and FK 506, when the 
parent CyA is measured by HPLC. Since the terminal 
half-life of Cy A could be as long as 9 days in some patients 
with poor liver function, combined use of Cy A and FK 506 
will result in renal impairment due to additive or synergis-
tic nephrotoxicity. The observed synergistic advantages of 
CyA and FK 506 in vitro and in animal models cannot be 
extended to clinical practice because of the nephrotoxic 
effects of these drugs. 
Table 2. Mean CyA Pharmacoklnetlc Results and Kidney Function 
Volume of FK 506 Plasma Serum 
Clearance ea~ Ute olstr1bution Concentration Creatinine 
Day (mUmin per kilogram [SOil (hours [SDIl (l/1<g [SO)) (ng/mL [SOil (rng/dL (SO]) 
l 5.6 ± 3.3 9.9 ± 3.4 3.1 ± 2.1 0 1.6 ± 0.7 6.5 ± 3.3 10.4 ± 3.1 3.1 ± 1.3 2.9 ± 2.2 6.8 ± 7.5 9.3±3.1 4.8 ± 6.3 2.0 ± 1.4 3.0 ± 1.3 2.1 ± 0.9 
P)6alue .86 .89 .70 .69 .045 
Significance NS NS N" ~I NS 5 
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Table 3. FK 506 Plasma Concentrations (ng/mL) 
Patient Day 0 Day2t 
R.F" 0.4 
L.W" 0.3 
0.5. 5.0 
M.B. 5.2 
W.O. 1.6 
O.w. 5.1 
H.w. 3.0 
Mean (SO) 2.9 (2.2) 
'Plasma separated at room temperature. 
tTwenty.four-hour through after 0.15 mg/kg IV FK 506. 
*Twelve-hour through after 0.15 mg/kg PO FK 506. 
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